The PI discovered the first metastasis suppressor gene, Nm23. Basic and translational research has investigated the role of Nm23 in the regulation of tumor metastasis. Eleven transfection studies have documented that overexpression of Nm23 in various tumor cell lines resulted in a 50-90% decrease in tumor metastatic potential in vivo. The mechanism of Nm23 suppression of metastasis is likely complex. Previous work has demonstrated a histidine protein kinase activity for Nm23 and identified Ksr and disruption of the Erk signaling pathway as substrates. Another potential mechanism of action of Nm23 is through binding to other proteins. This project asked, in an unbiased manner, which proteins bind to a Flag tagged Nm23-H1 and -M1 in vitro and in vivo. Murine 4T1 cells were implanted in the mammary fat pad (mfp), a primary tumor was removed 10 days later, and metastases were evident in spleen, liver, lung and lymph nodes eight weeks post-injections. Transfection of 4T1 cells with Nm23-H1 and -M1 inhibited metastasis to the liver by 69% and 75%, respectively. Nm23-H1 co-immunoprecipitating proteins have been identified from from 4T1 cells in vitro, primary in vivo tumors and metastases. A previously undisclosed interaction of Nm23 and gelsolin has been validated. Nm23 interaction with Gelsolin has been demonstrated to retard Gelsolin depolymerization of actin and enhancement of metastasis in vivo in two model systems. The data offer a potential mechanistic explanation for Nm23's anti-metastatic effects. One of the potential avenues to "drug" a suppressor gene is to identify inverse correlates of its expression. The lysophosphatidic acid receptor (LPA1), a G-protein coupled receptor for the serum lysophosphatidic acid (LPA) was found to be inversely related to Nm23 expression in cell lines, human breast tumors, and knock-out animal tissues. Forced re-expression of LPA1 overcame Nm23 suppression of tumor cell motility in vitro and metastasis in vivo. We hypothesized that an inhibitor of LPA1 would act as a metastasis suppressor and have preclinically validated Debio 0719. Administration of 0719 to animals injected into the mammary fat pad with murine 4T1 cells had no effect on primary tumor size. After surgical removal of the primary tumor, metastasis in the lymph nodes, lungs and liver was quantified 10 weeks post-injection. 0719 induced a significant suppression of metastasis in all sites. Other 4T1 experiments demonstrated that shRNA down-regulation of LPA1 also prevented metastasis, and is the mechanism of action of 0719. Treatment with 0719 only after mammary fat pad removal, akin to adjuvant therapy, was also metastasis suppressive. Confirmatory experiments showed a non-significant effect of 0719 on MDA-MB-231T human breast tumor growth in the mammary fat pad, but a significant inhibition of lung colonization after tail vein injection. When animals injected with MDA-MB-231T cells were treated with 0719 and the drug was removed, death ensued. Analysis of tissue from vehicle and 0719 treated animals showed that: (1) proliferation measured by Ki67 staining was high and equivalent in primary tumors treated with vehicle or 0719, but was reduced in lung and liver metastases treated with 0719;(2) similar trends were observed in pErk staining;(3) the opposite trend was osberved for p-p38 staining- no difference was observed in primary tumors, but 0719 treated lung and liver metastases exhibited higher levels of expression than vehicle controls. The data indicate that 0719 induced site specific dormancy in metastasis, a novel indication for a drug to date. The mechanism of metastatic dormancy is under investigation. These data, to our knowledge, represent the first drug candidate to induce metastatic dormancy. Current efforts aim to translate this finding to the clinic. We have completed a M-CRADA with Sanofi to use their compound SAR10082, an orally available LPA1 inhibitor under development for fibrosis, in similar preclinical models. In a high risk, high impact effort, I have collaborated with Dr. George Sledge to identify inverse expression correlates for multiple metastasis suppressor genes, not just Nm23. Using a gene expression analysis of siRNA knockdown of 19 metastasis suppressors, fifteen genes have been identified that are each inversely correlated to at least five, and up to eighteen metastasis suppressors. The gene PDE5a has been shown to be inversely expressed with multiple metastasis suppressors, and to enhance metastasis in vivo.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Cancer Institute Division of Clinical Sciences
Zip Code
Marino, Natascia; Collins, Joshua W; Shen, Changyu et al. (2014) Identification and validation of genes with expression patterns inverse to multiple metastasis suppressor genes in breast cancer cell lines. Clin Exp Metastasis :
Spano, Daniela; Marshall, Jean-Claude; Marino, Natascia et al. (2013) Dipyridamole prevents triple-negative breast-cancer progression. Clin Exp Metastasis 30:47-68
Lu, Jing; Steeg, Patricia S; Price, Janet E et al. (2009) Breast cancer metastasis: challenges and opportunities. Cancer Res 69:4951-3
Lee, Jong Heun; Marshall, Jean-Claude; Steeg, Patricia S et al. (2009) Altered gene and protein expression by Nm23-H1 in metastasis suppression. Mol Cell Biochem 329:141-8
Marshall, Jean-Claude; Lee, Jong Heun; Steeg, Patricia S (2009) Clinical-translational strategies for the elevation of Nm23-H1 metastasis suppressor gene expression. Mol Cell Biochem 329:115-20
McDermott, William G; Boissan, Mathieu; Lacombe, Marie-Lise et al. (2008) Nm23-H1 homologs suppress tumor cell motility and anchorage independent growth. Clin Exp Metastasis 25:131-8
Steeg, Patricia S; Horak, Christine E; Miller, Kathy D (2008) Clinical-translational approaches to the Nm23-H1 metastasis suppressor. Clin Cancer Res 14:5006-12
Steeg, Patricia S; Theodorescu, Dan (2008) Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol 5:206-19
Steeg, Patricia S (2008) Heterogeneity of drug target expression among metastatic lesions: lessons from a breast cancer autopsy program. Clin Cancer Res 14:3643-5
Horak, Christine E; Lee, Jong Heun; Marshall, Jean-Claude et al. (2008) The role of metastasis suppressor genes in metastatic dormancy. APMIS 116:586-601

Showing the most recent 10 out of 11 publications